Abstract: The present invention is directed to methods for reducing cross-reactivity between species employed in multiplexed immunoassays.

Abstract: Provided is a method of quantitatively determining the ability of individual IgG heavy chains to selectively pair with a particular IgG light chain when the heavy chains and two unique light chains are co-expressed. The method provides results with reasonable throughput and is robust and accurate. The co-expressed heavy and light chains do not need to be isolated and purified which enables more efficient screening.

Abstract: The present invention concerns methods for the detection f target molecules in a sample including several steps of signal amplification allowing the detection of a very low number of target molecules in the tested sample. The detection assay is based on the use of a universal probe which enables the signal amplification. The specific recognition of the target molecule is achieved by using a specific binding agent, preferably an aptamer. The invention further concerns kits and methods for the diagnosis of pathological conditions.

Abstract: A biosensor comprises first and second molecular components and is capable of displaying protease activity in response to a binding event mediated by first and second binding partners of the biosensor. The first and second binding partners may bind each other directly or may both bind a target molecule. At least the first molecular component comprises an autoinhibited protease, whereby the binding event switches the protease frora an autoinhibited inactive state to a protease active state. The second molecular component may activate the protease of the first molecular component by binding a cross-binder which releases the autoinhibitor or by cleaving a linker which releases the autoinhibitor. The first and second molecular components may both have autoinhibited proteases which reciprocally activate each other.

Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.

Abstract: Disclosed is a biosensor engineered to conditionally respond to the presence of specific small molecules, the biosensors including conditionally stable ligand-binding domains (LBDs) which respond to the presence of specific small molecules, wherein readout of binding is provided by reporter genes or transcription factors (TFs) fused to the LBDs.

Abstract: The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.

Abstract: A system, device, and method for rapid detection of analytes that includes a living, engineered biosensor cell that is typically a component of the mammalian immune system; a reporter protein that is engineered into and expressed by the living, engineered biosensor cell, wherein the reporter protein emits a detectable signal in response to certain predetermined changes in the cytosol of the living, engineered cell; a signal transduction pathway expressed by the living, engineered biosensor cell, wherein the signal transduction pathway controls a biological process within the cytosol of the living, engineered biosensor cell, and wherein the biochemical process, when it occurs, causes the reporter protein to emit a detectable signal; at least one type of detector molecule that is adapted to bind to a specific analyte; at least one analyte that binds to the detector molecule that is specific to that analyte; a plurality of non-antibody signal transducing elements that are either expressed by the living, engineer

Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.

Abstract: The present invention provides a method for screening compounds for their ability to inhibit autophosphorylation of Janus kinase 3 in the absence of any additional substrate. The present invention also provides a method for screening compounds that bind to Janus kinase 3 domains other than the kinase domain, to identify synthetic or natural compounds including biomolecules, that modulate Janus kinase 3 activity. This invention also describes a multi-component screening kit composed of purified recombinant Janus kinase 3 proteins and recombinant phosphorylated Janus kinase 3 fusion proteins including, one or more phosphorylated or non-phosphorylated domain-deleted Janus kinase 3 fusion proteins.

Abstract: A method for predicting myocardial damage in a subject having or at risk of cardiac disease includes determining a level of apolipoprotein AI (ApoAI) and a level of Coenzyme Q10 (CoQ10) in the subject and comparing the determined levels of ApoAI and CoQ10 to control levels.

Abstract: Compositions, methods, articles of manufacture, and kits are provided for storage and delivery of proteins.

Abstract: The present invention relates to a method for analyzing the pattern of live intercellular membrane protein binding. The method for analyzing the pattern according to the present invention can analyze accurately, sensitively, quickly, and readily the binding pattern of a target membrane protein and a candidate substance to be specifically bound therewith without tagging to a ligand, and thus measure directly and accurately the position and quantitative information of the binding of the membrane protein and the target substance. Such effects make it possible to apply the method for various uses such as dissociation constant, mutant study, complex formation, and signal transduction. Moreover, it is expected to use the method for searching out undiscovered membrane proteins and target substances.

Abstract: This invention relates to a peptide comprising or consisting of at least 8 consecutive amino acid residues of the sequence set forth in SEQ ID NO: 3, provided that said peptide does not consist of the sequence set forth in SEQ ID NO: 3, or a corresponding peptidomimetic, wherein said peptide or peptidomimetic binds to an anti-KIR4.1 antibody comprised in a sample from a patient having multiple sclerosis or a predisposition therefor. The present invention furthermore relates to a method for diagnosing multiple sclerosis or a predisposition for multiple sclerosis in a subject, the method comprising determining the presence of an anti-KIR4.1 antibody in a sample obtained from said subject, wherein the presence of an anti-KIR4.1 antibody in said sample is indicative of multiple sclerosis or a predisposition for multiple sclerosis. Also provided are novel means and methods for the therapy of multiple sclerosis.

Abstract: Provided herein are compositions useful in detecting degradative enzymes and biomolecules in bodily fluid samples.

Abstract: Provided is a monoclonal antibody specifically reactive with a C-terminal neo-epitope of PIIINP comprised in a C-terminal amino acid sequence CPTGXQNYSP-COOH (SEQ ID NO: 4) in which X is Gly or Pro, and where the monoclonal antibody does not recognize or bind an elongated version of the C-terminal amino acid sequence CPTGXQNYSPQZ-COOH (SEQ ID NO: 5), in which Z is absent or is one or more amino acids of the sequence of collagen type III. Also provided is a method of immunoassay for detecting in a biological sample the C-terminal neo-epitope of PIIINP generated by N-protease cleavage of intact type III procollagen, by contacting the sample with the monoclonal antibody, and determining the amount of binding of the antibody.

Abstract: Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.

Abstract: The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.

Abstract: The present invention relates to a method for detecting food poisoning bacteria, and more particularly, to a method for rapidly and quantitatively isolating food poisoning bacteria contents which contaminate food and the like. The method according to the present invention is characterized by including the steps of: introducing magnetic nanoparticles which can bind to bacteria into a sample for measuring the bacteria so as to bind the magnetic nanoparticles to the bacteria; isolating the magnetic nanoparticles; passing the nanoparticles which are isolated by using magnetism through a solution having high viscosity so as to separate the magnetic nanoparticles to which bacteria are bound from magnetic nanoparticles to which no bacteria are bound; and quantifying the magnetic nanoparticles to which bacteria are bound.

Abstract: The invention provides a method for detecting one or more biological ligands, where the method generally uses two arrays of biological reagents. The two arrays have two different functionalities: the first array captures the ligands on the array; and the second array delivers detecting reagents to the captured ligands. Use of arrays affords the method high-throughput detection capability; and the use of two different arrays ensures high specificity. The first array has a support structure fixed with a first set of reagents, each at a pre-determined position on the support. The second array has a support structure fixed with a second set of reagents, each at a pre-determined position on the support. The first array contains reagent(s) binding to a ligand, while the second array contains second reagent(s) binding to the same ligand. In preferred embodiments, antibodies are used as reagents, and used in detecting proteins in protein samples.